Intensity Therapeutics, Inc. SEC filings INTS

Intensity Therapeutics, Inc. has 246 filings in SEC EDGAR's recent list, going back to Jan 18, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 30, 2026 —
DEF 14A Proxy statement Apr 30, 2026 Apr 30, 2026
DEFA14A Additional proxy material Sep 9, 2025 —
DEF 14A Proxy statement Sep 9, 2025 Sep 9, 2025
PRE 14A Preliminary proxy statement Aug 28, 2025 Aug 28, 2025
DEFA14A Additional proxy material Jun 2, 2025 —
DEF 14A Proxy statement Jun 2, 2025 Jun 2, 2025
DEFA14A Additional proxy material Jun 4, 2024 —
DEF 14A Proxy statement Jun 4, 2024 Jun 4, 2024

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INTS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Shelton, CT
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1567264

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.